Top Markets
Coin of the day
Celyad Oncology S.A. Celyad Oncology S.A.

Celyad Oncology S.A.

CYAD
Rang in Aktien #30917
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Aktienkurs
$0.33686807
Marktkapitalisierung
$15.08M
Veränderung (1 Tag)
1.79%
Veränderung (1 Jahr)
-26.73%
Land
BE
Handel Celyad Oncology S.A. (CYAD)

Kategorie

Preis CYAD mit Marktkapitalisierung von B
Celyad Oncology S.A. Celyad Oncology S.A.
CYAD
$0.33686807
Marktkapitalisierung von Celyad Oncology S.A.(CYAD)
Marktkapitalisierung: $15.08M
Mit Stand August 2026 hat Celyad Oncology S.A. eine Marktkapitalisierung von $15.08M. Das macht Celyad Oncology S.A. laut unseren Daten zum 30917th wertvollsten Unternehmen der Welt nach Marktkapitalisierung. Die Marktkapitalisierung ist der Gesamtmarktwert aller ausstehenden Aktien eines börsennotierten Unternehmens und wird häufig verwendet, um den Unternehmenswert zu bestimmen.
Marktkapitalisierung von Celyad Oncology S.A. von 2013 bis 2026
CYAD im Vergleich zu den Top 5 der beliebtesten stocks
Preis für CYAD Vermögenswert B Marktkapitalisierung von B Ergebnisse
Celyad Oncology S.A. Celyad Oncology S.A.
$118,874 $15.08M
$5.321T +35,288,012.11%
Celyad Oncology S.A. Celyad Oncology S.A.
$100,694 $15.08M
$4.507T +29,891,131.52%
Celyad Oncology S.A. Celyad Oncology S.A.
$92,278.82 $15.08M
$4.131T +27,393,063.72%
Celyad Oncology S.A. Celyad Oncology S.A.
$79,872.69 $15.08M
$3.575T +23,710,278.66%
Celyad Oncology S.A. Celyad Oncology S.A.
$62,475.52 $15.08M
$2.797T +18,545,890.86%